Multicenter phase 2 study of talazoparib plus avelumab for recurrent mismatch repair proficient endometrial cancer
Dr. Panagiotis Konstantinopoulos
Although the activity of the FDA-approved regimen of pembrolizumab and lenvatinib for mismatch repair proficient endometrial cancer (MMRP EC) is compelling, most patients do not tolerate, do not respond to, or develop resistance to this regimen. A phase 2 study at four US centers evaluated the combination of talazoparib (PARP inhibitor) and avelumab (anti-PD-L1) for MMRP EC. This combination had a favorable toxicity profile and met the predetermined criteria to be considered worthy of further evaluation.
